Laboratory Findings in Delayed Hemolytic Transfusion Reaction
In a delayed hemolytic transfusion reaction (DHTR), expect a positive direct antiglobulin test (DAT/Coombs) with strong C3d positivity and a newly identified alloantibody in the antibody screen that was absent pretransfusion.
Key Laboratory Findings
Direct Antiglobulin Test (Coombs)
- Positive DAT is the hallmark finding, typically appearing 24 hours to 28 days post-transfusion 1
- C3d (complement) positivity is universal and strongly positive in all DHTR cases, even when the causative antibodies are not traditionally thought to activate complement 2
- C3d remains detectable on circulating red cells for weeks to months after the reaction 2
- IgG coating is less reliably detected - the DAT shows IgG in only 38% of cases by standard testing (10 of 26 cases), though sensitive assays can detect small amounts in most patients 2
- The DAT typically remains positive long-term, with 80% (12 of 15) still showing positive anti-IgG results up to 174 days after reaction 3
Antibody Screen
- A newly developed alloantibody specificity appears in serum/plasma that was not present in pretransfusion testing 1, 3
- The most common culprits are anti-E and anti-Jka, accounting for 70% of cases 3
- Other frequent antibodies include anti-K, anti-Fya, anti-Fyb, anti-c, and anti-D 2
- The causative alloantibody can be eluted from circulating red cells and may remain recoverable for over 100 days post-transfusion 2
Clinical Context and Timing
DHTR is defined by 4:
- Significant hemoglobin drop within 21 days post-transfusion
- New red cell alloantibody detection
- Accelerated HbS% increase with concomitant HbA fall (in sickle cell patients)
- Inadequate post-transfusion hemoglobin rise (<1 g/dL) or rapid fall back to pretransfusion levels 1
Additional Laboratory Evidence of Hemolysis
- Elevated LDH from baseline 4
- Hemoglobinuria 4
- Reticulocytopenia or reticulocytosis changes from baseline 4
Critical Pitfall
The DAT pattern is NOT "mixed-field" - it shows uniform strong positivity for C3d across all circulating red cells, suggesting complement binds not only to transfused donor cells but also to the patient's autologous red cells 2. This distinguishes DHTR from simple detection of incompatible transfused cells.
Distinguishing DHTR from Delayed Serologic Transfusion Reaction (DSTR)
Only 18% of patients with positive DAT and new alloantibody (DSTR) show clinical/laboratory evidence of hemolysis qualifying as true DHTR 3. The incidence of DSTR is 0.66% versus DHTR at only 0.12% of transfused patients 3.